Startups Manhattan Genomics, Preventive Revive Embryo CRISPR

A New Push Into Heritable Genome Editing

Six years after scientist He Jiankui triggered global outrage by creating the first gene-edited babies, two newly surfaced biotech startups, Manhattan Genomics and Preventive, are openly pursuing heritable genome editing in human embryos, reigniting one of the most contentious debates in modern science 1. Unlike He's clandestine and widely condemned experiment, these ventures are reportedly operating in the open, but their ambitions carry the same fundamental risk: introducing DNA changes that would pass down to future generations 1. Separately, researchers have already demonstrated gene editing on human zygotes, the single-cell stage of embryos, in work that scientists warn could normalize further embryo manipulation and "open the floodgates" to broader genetic tinkering 48. Critics quoted in that coverage specifically flagged the risk that such techniques become a "gateway to embryo editing to do enhancements," rather than staying confined to treating disease 8.

Why the Ethical Alarm Bells Are Ringing Again

The controversy isn't just about technical feasibility — it's about who gets to decide which traits or conditions are worth eliminating. Physician and author Dr. Neal Baer has raised pointed questions about the eugenic undertones of aggressive gene-editing ambitions, asking bluntly, "who are we to say they shouldn't exist?" in reference to people with genetic conditions that editing technologies might target for elimination 3. That tension is visible in adjacent research: Japanese scientists have used CRISPR to remove the extra chromosome responsible for Down syndrome and restore typical cell function, a breakthrough framed as therapeutic but one that sits squarely inside the same ethical minefield Baer describes 23.

CRISPR's Expanding Footprint Beyond Embryos

While embryo editing draws the most controversy, CRISPR's broader momentum continues on multiple fronts. Intellia Therapeutics announced Phase 3 results for Lonvo-Z (lonvoguran ziclumeran), described as the world's first in-vivo CRISPR therapy, reporting an 87% efficacy figure that observers called a landmark moment for genetic medicine 5. Gene editing has also moved into veterinary science, with researchers editing a dog's genome as a proof of concept that could eventually help address canine health problems, a development one lead author suggested is only the beginning 7. Meanwhile, CRISPR-based screening and editing tools continue to reshape genomics research more broadly, expanding their role as foundational infrastructure for biotech innovation 9.

Funding, Innovation, and Lingering Caution

The rush of embryo-editing startups arrives alongside broader questions about how innovation itself is generated in biotech. Jennifer Doudna, one of CRISPR's original inventors, has voiced skepticism that artificial intelligence will soon replace human ingenuity in scientific discovery, arguing that genuinely novel ideas still originate with people rather than chatbots 6. That perspective underscores the current moment: biotech funding and ambition are accelerating rapidly across therapeutic, veterinary, and embryonic applications, even as the field's most senior voices and ethicists urge restraint. Together, the coverage suggests CRISPR is entering a pivotal phase — one defined simultaneously by genuine medical breakthroughs and by unresolved, deeply human questions about where gene editing's boundaries should lie.